RUTHERFORD, N.J., July 08, 2025 - Glucotrack, Inc. (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants, totaling approximately 49,700 units, from holders as of June 30, 2025. This transaction is part of the company's strategy to strengthen its capital structure and reduce share dilution, funded with existing cash. The repurchase reflects Glucotrack's confidence in its long-term implantable continuous blood glucose monitoring system for diabetes patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.